SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

Solutions for Duchenne Muscular Dystrophy

OPTIMIZE DUCHENNE MUSCULAR DYSTROPHY TRIALS FOR BETTER OUTCOMES

Ongoing research is critical in the continued effort to identify safe and effective therapies or treatments for people affected by Duchenne Muscular Dystrophy (DMD). Signant Health can apply decades of direct clinical experience, deep therapeutic-area expertise, and innovative clinical trial technologies within our Signant SmartSignals™ suite to help researchers support DMD endpoints.

STREAMLINE COA MANAGEMENT

With many types and versions of home- and site-based clinical outcome assessments involved in DMD trials, managing data capture and ensuring data quality can be challenging. Simplify COA administration and the participation experience, optimize data quality, and launch studies quickly with our comprehensive eCOA platform.

IMPROVE CLINICAL RATINGS ACCURACY & CONSISTENCY

Inconsistencies in assessment administration and scoring can lead to difficulties interpreting the data. Signant's Rater Training program focuses on qualifying raters and standardizing assessment technique to reduce inter- and intra-rater variability as well as mitigate placebo response. Video capture and expert reviews by our in-house Duchenne experts can also be leveraged to ensure endpoint reliability.

MAXIMIZE SUPPLY CHAIN EFFICIENCY

Signant's RTSM solution can be implemented rapidly in just one to four weeks and utilizes a unique algorithm to dynamically optimize IP usage for global studies. We focus on reducing waste, reconciliation/returns efforts, and the number of shipments required to ensure compounds for these studies do not go to waste through overages or expiration.

OPTIMIZE ENDPOINT RELIABILITY

Guide investigative staff through proper ClinRO assessment technique using our enhanced clinician ratings platform. Automated scoring, branching logic, and built-in edit checks help reduce errors. When paired with Blinded Data Analytics, we can proactively monitor data in real-time, creating opportunities to mitigate risks before they impact your study data.

LEVERAGE OUR DUCHENNE RESEARCH EXPERTS

From consulting on outcome measure selection and implementation to reducing burdens on sites and patients, Signant's in-house experts will help you navigate common DMD challenges throughout the study lifecycle. Talk through your protocol with our clinical science and medicine experts experienced in neuromuscular, rare disease, and pediatric studies.

DIGITALIZE THE PROCESS

Each solution and service within our Signant SmartSignals evidence generation platform can be applied to a study independently. However, when combined, they create an intuitive and powerful digital ecosystem for creating and managing complex global studies. Plus, every study is supported by a dedicated team of clinical science and operations experts.

With Signant, you gain a single-source partner for comprehensive evidence generation and trial optimization solutions that support the full clinical trial lifecycle.

SIGNANT'S DMD CLINICAL TRIAL EXPERIENCE

Phases

I II III IV



16 Languages

830+ Sites

27 Countries

2,500+ Patients

29 Studies

SMARTSIGNALS SUITE

SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

Blinded Data Analytics

RTSM

Rater Training & Qualification

Scientific Advisory

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS